ArticleDiagnostics (Basel, Switzerland)2021
Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Immunohistochemical Analyses Using Markers for Mesonephric, Endometrioid and Serous Tumors.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Evaluation of CD10 Expression in Endometrial Carcinoma: A Systematic Review.Iranian journal of pathology · 2026Review
- Multi-institutional study of mesonephric-like adenocarcinoma: its clinicopathological characteristics and histogenetic association with ectopic endometrium.Virchows Archiv : an international journal of pathology · 2026Article
- Mesonephric-Like Adenocarcinoma of the Endometrium: A Rare and Diagnostically Challenging Entity.Cureus · 2026Article
- The TTF-1 and Napsin A Trap: Metastatic Endometrial Carcinoma Masquerading as Lung Primary.International journal of surgical pathology · 2026Article
- Endocrine Therapy for Endometrial Carcinoma: Current Evidence, Resistance Mechanisms, and Biomarker-Driven Patient Selection.Current oncology (Toronto, Ont.) · 2026Review
- Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026Review
- Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER Status.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026Article
- Review
- Endometrial mesonephric-like adenocarcinoma: Clinicopathologic features, treatment, and outcomes.Biomolecules & biomedicine · 2025Article
- Validation of 2023 FIGO Stage IA1-IIIC2 Endometrial Carcinoma: A Retrospective Analysis of Two Tertiary Centers in South Korea and Taiwan.Cancer research and treatment · 2025Article
- Case report: Mesonephric-like carcinoma of the endometrium in a 73-year-old female.International journal of surgery case reports · 2025Article
- Controversies in the Management of Mesonephric and Mesonephric-Like Adenocarcinomas of the Female Genital Tract.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Review
- Dedifferentiated Leiomyosarcoma of the Uterine Corpus with Heterologous Component: Clinicopathological Analysis of Five Consecutive Cases from a Single Institution and Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2024Article
- Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations.Journal of cancer research and clinical oncology · 2023Review
- Article
- Case Report: The first report of PPP2R1A mutations in mesonephric-like adenocarcinoma of endometrial carcinoma.Frontiers in oncology · 2023Article
- Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics.Diagnostics (Basel, Switzerland) · 2022Article
- Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics.Diagnostics (Basel, Switzerland) · 2022Article
- Mesonephric Adenocarcinoma of the Vagina HarboringDiagnostics (Basel, Switzerland) · 2022Article
- Mesonephric-Like Adenocarcinoma of Uterine Corpus: A Clinicopathological and Targeted Genomic Profiling Study in a Single Institution.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Mesonephric-like adenocarcinoma (MLA) of the uterine corpus is a rare but distinct malignant tumor of the female genital tract, demonstrating a characteristic morphology and unique immunohistochemical profiles and molecular alterations. We conducted immunohistochemical staining (IHC) to make precise differential diagnoses of uterine MLAs from common histological subtypes of endometrial carcinomas. We collected 25 uterine MLAs and performed IHC for GATA3, TTF1, CD10, ER, PR, p16, p53, and HER2. Seventeen cases (68.0%) showed at least moderate nuclear GATA3 immunoreactivity in ≥25% of tumor cells. Most cases expressed TTF1 (17/21, 81.0%) and CD10 (luminal; 17/21, 81.0%). Heterogeneous TTF1 expression was noted in 12 cases. An inverse pattern of GATA3 and TTF1 staining was observed in eight cases (32.0%). Three cases (12.0%) showed moderate-to-strong ER expression in ≥25% of tumor cells, and two cases (8.0%) showed moderate-to-strong PR expression in ≥5% of tumor cells. These hormone receptor-positive MLAs varied in intensity and proportion of GATA3 staining. None of the 25 cases exhibited either diffuse and strong p16 expression or aberrant p53 expression. Five cases (20.0%) showed equivocal HER2 immunoreactivity (score 2+), but
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.